6CM
TARA icon

683 Capital Management’s Protara Therapeutics TARA Stock Holding History

683 Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,429
Closed -$330K – 229
2024
Q4 		$330K Buy
+62,429
New +$202K 0.02% 194

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

683 Capital Management's TARA Position: Q1 2025 in Review

683 Capital Management sold out of Protara Therapeutics (TARA) in Q1 2025, closing a stake of 62,429 shares — an estimated $330K sold.

683 Capital Management first reported a position in TARA in Q4 2024 and held it in 1 quarter. The position peaked at $330K in Q4 2024. 59 funds tracked by Wall St. Rank hold TARA as of Q1 2025.

  • 683 Capital Management reported no remaining Protara Therapeutics position as of Q1 2025 after selling out during the quarter.
  • 683 Capital Management sold 62,429 Protara Therapeutics shares in Q1 2025, an estimated $330K.
  • 683 Capital Management first reported a position in Protara Therapeutics in Q4 2024 and held it in 1 quarter.
  • 683 Capital Management's Protara Therapeutics position peaked at $330K in Q4 2024.
  • 59 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.